Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
Quince Therapeutics, Inc. (NASDAQ: QNCX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $6.00 price target on the stock.
Quince Therapeutics, Inc. (NASDAQ: QNCX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.